Moral hazard in physician prescription behavior

Berndt, 1995, Information, marketing, and pricing in the U.S. antiulcer drug market, American Economic Review, 85, 100 Blomqvist, 1991, The doctor as double agent: information asymmetry, health insurance, and medical care, Journal of Health Economics, 10, 411, 10.1016/0167-6296(91)90023-G Butler, 1982, A computationally efficient quadrature procedure for the one-factor multinomial probit model, Econometrica, 50, 761, 10.2307/1912613 Chamberlain, 1980, Analysis of covariance with qualitative data, Review of Economic Studies, 47, 225, 10.2307/2297110 Coscelli, A., 1998. Are market shares in drug markets affected by doctors' and patients' preferences for brands? Discussion Paper 98-01, University College London. Dranove, 1989, Medicaid drug formulary restrictions, Journal of Law and Economics, 32, 143, 10.1086/467172 Grabowski, 1992, Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Reform Act, Journal of Law and Economics, 35, 331, 10.1086/467257 Greene, 1990 Guilkey, 1993, Estimation and testing in the random effects probit model, Journal of Econometrics, 59, 301, 10.1016/0304-4076(93)90028-4 Heckman, 1981, Statistical models for discrete panel data Heckman, 1976, Estimation of a stochastic model of reproduction: an econometric approach Hellerstein, 1998, The importance of the physician in the generic versus trade-name prescription decision, Rand Journal of Economics, 29, 108, 10.2307/2555818 Hurwitz, 1988, Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals, Journal of Law and Economics, 31, 299, 10.1086/467158 Maddala, 1987, Limited dependent variable models using panel data, The Journal of Human Resources, 22, 307, 10.2307/145742 Pauly, 1968, The economics of moral hazard: comment, American Economic Review, 58, 531 Schwartzman, 1976 Zweifel, 1997